Gross Total Resection and Recurrence-Free Survival in Diffuse Gliomas: A Single-Center Cohort Study from Eastern Europe
Clinics and Practice · 20.08.2026 · 16 (8) · 155
DOI: 10.3390/clinpract16080155 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinics and Practice, online erschienen am 20.08.2026. Verfasst von Teodor Cristian Blidaru und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: The independent contribution of extent of resection (EOR) to early recurrence in diffuse gliomas remains debated, as crude analyses are confounded by tumor biology, and real-world data from Eastern European centers are scarce.
Methods
We retrospectively studied 283 consecutive adults with surgically treated diffuse gliomas (2021–2024) at a Romanian tertiary center. Primary endpoints were recurrence-free survival (RFS) at 1 and 2 years, evaluated as landmark endpoints; secondary endpoints were overall recurrence, reoperation, and reirradiation. Clinical, histopathological, surgical, imaging, and treatment variables were analyzed with complete-case Firth-penalized logistic regression.
Results
Among evaluable patients, 70.6% (132/187) were recurrence-free at 1 year and 64.2% (120/187) at 2 years; overall recurrence occurred in 53.7% (139/259). After adjustment, gross total resection (GTR) was independently associated with higher odds of remaining recurrence-free at 1 year (OR 12.37, 95% CI 3.23–52.58; p < 0.001) and 2 years (OR 10.56; p < 0.001), as was subtotal resection (STR) at both time points (OR 4.15, 95% CI 1.17–16.16, p = 0.027; and OR 3.93, p = 0.027), versus partial resection/biopsy.
Conclusions
EOR was independently associated with early RFS, supporting maximal safe resection as a primary surgical objective. The landmark endpoints were not evaluable in 96 of 283 patients, almost all of whom underwent biopsy or partial resection, so the odds ratios indicate the direction of the effect and not its precise magnitude. Overall recurrence, evaluable in 91.5% of the cohort, showed a concordant gradient. External validation is needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
- Neuroaxis Neurology Clinic, 040215 Bucharest, Romania.
- Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
- Department of Genomics, Medfuture Institute for Biomedical Research, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
ORCID-Profile: Teodor Cristian Blidaru, Marius Cristian Zaharia, Natalia Blidaru, Stefan Strilciuc
Zitieren
APA
Blidaru, T. C., Zaharia, M. C., Mitrea, D., Marin, R. M., Blidaru, N., Ghica, M., Matei, M. S., Papacocea, R., Strilciuc, S., & Garofil, D. N. (2026). Gross Total Resection and Recurrence-Free Survival in Diffuse Gliomas: A Single-Center Cohort Study from Eastern Europe. Clinics and Practice, 16(8), 155. https://doi.org/10.3390/clinpract16080155
Vancouver
Blidaru TC, Zaharia MC, Mitrea D, Marin RM, Blidaru N, Ghica M, et al. Gross Total Resection and Recurrence-Free Survival in Diffuse Gliomas: A Single-Center Cohort Study from Eastern Europe. Clinics and Practice. 2026;16(8):155. doi:10.3390/clinpract16080155
BibTeX
@article{Blidaru2026,
author = {Blidaru, Teodor Cristian and Zaharia, Marius Cristian and Mitrea, Dan and Marin, Raluca Maria and Blidaru, Natalia and Ghica, Manuela and Matei, Maria Sinziana and Papacocea, Raluca and Strilciuc, Stefan and Garofil, Dragos Nicolae},
title = {Gross Total Resection and Recurrence-Free Survival in Diffuse Gliomas: A Single-Center Cohort Study from Eastern Europe},
journal = {Clinics and Practice},
year = {2026},
volume = {16},
number = {8},
pages = {155},
doi = {10.3390/clinpract16080155}
}
EUVIMED